Defective apoptosis is a hallmark of the progression of B chronic lymphocytic leukemia (B-CLL). Smac-mimetics have been shown to induce apoptosis in several tumors. We describe the in vitro pro-apoptotic activity and regulation of the mol. pathway induced by new Smac-mimetics in B-CLL. The cytotoxic effect was significantly higher in B-CLL samples than in healthy controls. No significant synergistic effect was obsd. in combined treatment. In conclusion one of our compds. (Smac66), used as monotherapy and not in combination, is highly active against B-CLL cells thus suggesting a promising therapeutic potential as a new class of antileukemic drugs in haematol.
Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL) / C. Scavullo, F. Servida, D. Lecis, F. Onida, C. Drago, L. Ferrante, P. Seneci, W. Barcellini, M. Lionetti, K. Todoerti, A. Neri, D. Delia, G. Lambertenghi Deliliers. - In: LEUKEMIA RESEARCH. - ISSN 0145-2126. - 37:7(2013), pp. 809-815. [10.1016/j.leukres.2013.03.016]
Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL)
F. Onida;P. Seneci;M. Lionetti;K. Todoerti;A. Neri;G. Lambertenghi DeliliersUltimo
2013
Abstract
Defective apoptosis is a hallmark of the progression of B chronic lymphocytic leukemia (B-CLL). Smac-mimetics have been shown to induce apoptosis in several tumors. We describe the in vitro pro-apoptotic activity and regulation of the mol. pathway induced by new Smac-mimetics in B-CLL. The cytotoxic effect was significantly higher in B-CLL samples than in healthy controls. No significant synergistic effect was obsd. in combined treatment. In conclusion one of our compds. (Smac66), used as monotherapy and not in combination, is highly active against B-CLL cells thus suggesting a promising therapeutic potential as a new class of antileukemic drugs in haematol.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
